KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Intangibles (2016 - 2025)

Historic Intangibles for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $233.1 million.

  • Biomarin Pharmaceutical's Intangibles fell 1065.77% to $233.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.1 million, marking a year-over-year decrease of 1065.77%. This contributed to the annual value of $255.3 million for FY2024, which is 1337.73% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Intangibles stood at $233.1 million for Q3 2025, which was down 1065.77% from $239.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Intangibles ranged from a high of $405.9 million in Q1 2021 and a low of $233.1 million during Q3 2025
  • Over the past 5 years, Biomarin Pharmaceutical's median Intangibles value was $310.3 million (recorded in 2023), while the average stood at $317.3 million.
  • In the last 5 years, Biomarin Pharmaceutical's Intangibles tumbled by 632.26% in 2022 and then tumbled by 1598.0% in 2023.
  • Biomarin Pharmaceutical's Intangibles (Quarter) stood at $388.7 million in 2021, then fell by 12.89% to $338.6 million in 2022, then decreased by 12.96% to $294.7 million in 2023, then dropped by 13.38% to $255.3 million in 2024, then fell by 8.68% to $233.1 million in 2025.
  • Its Intangibles stands at $233.1 million for Q3 2025, versus $239.6 million for Q2 2025 and $247.3 million for Q1 2025.